Amentum (AMTM) Q3 2026 Earnings Preview & Nuclear Projects

Font: Financial Modeling Prep  • Aug 10, 2026

Amentum Holdings (NYSE:AMTM) Earnings Preview: Q3 2026 Outlook and Nuclear Project Exposure

• Amentum Holdings (NYSE:AMTM) is scheduled to discuss its fiscal third-quarter 2026 results on August 11, 2026, with analysts forecasting earnings per share (EPS) of $0.62 and revenue of $3.57 billion.
• The government services company has exposure to advanced nuclear projects, including a partnership with Rolls-Royce SMR to support small modular reactor deployment in the UK and Czech Republic.
• Analysts maintain a consensus Hold recommendation for Amentum Holdings, with an average 12-month price target of $32.00, alongside key financial metrics such as a price-to-earnings (P/E) ratio of 40.83 and a debt-to-equity ratio of 0.85.

Amentum Holdings (NYSE:AMTM), a leading government services and advanced engineering company, is preparing for its upcoming fiscal third-quarter earnings update. The company is involved in complex science, security, sustainability, and nuclear-related projects for government and commercial customers.

Amentum will host its fiscal Q3 2026 earnings conference call on August 11, 2026, at 8:30 AM EDT. The company said a news release containing the results will be issued before the call. The quarter ended on July 3, 2026.

For the quarter, Wall Street analysts expect earnings per share of $0.62. The consensus revenue estimate is $3.57 billion. Investors will watch whether the company can meet or exceed these expectations and whether management updates its outlook for the rest of the fiscal year.

Amentum also has exposure to the advanced nuclear sector. In January 2026, the company announced a partnership with Rolls-Royce SMR to support the first deployments of small modular reactors in the UK and Czech Republic. This highlights Amentum’s role in engineering, program delivery, and nuclear infrastructure projects.

Analysts currently have a consensus Hold recommendation for Amentum Holdings, according to MarketBeat. The average 12-month price target is $32.00. Recent analyst actions include an underperform rating from BNP Paribas Exane and an equal weight rating from Morgan Stanley, reflecting mixed views on the stock.

The company’s financial metrics show a price-to-earnings (P/E) ratio of 40.83, a debt-to-equity ratio of 0.85, and a current ratio of 1.48. These figures provide a snapshot of valuation, leverage, and short-term liquidity ahead of the earnings release.